Drugs / Govorestat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04117711 | Jun 2019 → Dec 2021 | classic galactosemia | Applied Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04902781 | Mar 2021 → Mar 2023 | classic galactosemia | Applied Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05418829 | Oct 2021 → Nov 2022 | classic galactosemia | Applied Therapeutics, Inc. | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT05397665 Comparator | Jan 2022 → Oct 2024 | neuronopathy, distal hereditary motor, autosomal recessive 8 | Applied Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT07191912 Comparator | May 2026 → Oct 2028 | neuronopathy, distal hereditary motor, autosomal recessive 8 | Applied Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-04 | Advanz Pharma | ADVANZ PHARMA to receive exclusive rights from Applied Therapeutics to commercialise AT-007 (govorestat) in Europe advanzpharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | govorestat | “orally administered once-daily govorestat (AT-007), a central nervous system penetrant aldose reductase inhibitor” PMID 39569553 ↗ Nov 2024 |
| Known as | AT-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397665 ↗ |
| Action | Inhibit | “AT-007 is a CNS and retina penetrant aldose reductase inhibitor.” NCT04117711 ↗ |
| Modality | Small molecule | — CHEMBL4650327 ↗ |
| Route | Oral | “Once daily oral escalating dose” NCT04117711 ↗ |